In-Vitro Inflammatory Bowel Disease Diagnostic Market

In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market Segmentation by Product (Assays/Biomarkers and Analyzers); by Disease Type (Ulcerative Colitis and Crohn’s Disease); by Disease Stage (Mild, Moderate, and Severe); by Test Type (Blood Tests, Stool Tests, Antibody Tests, and Biopsy); by Patient Demography (Pediatric, Adults, and Geriatric); by End-User (Hospitals, Clinics, Diagnostic Laboratories, & Others); and by Test Method – Global Demand Analysis & Opportunity Outlook 2019-2028

Buy Now
Report ID: 3414 | Published On: Apr 05, 2022
  1. Introduction
    • Market Definition
    • Market Segmentation
    • Product Overview
  2. Assumptions and Acronyms
  3. Research Methodology
  4. Research Process
    • Primary Research
    • Manufacturers
    • Distributors
    • End Users
    • Secondary Research
    • Market Size Estimation
  5. Executive Summary - Global Advanced Therapy Medicinal Products Market
  6. Analysis of Market Dynamics
  7. Drivers
  8. Trends
  9. Key Market Opportunities for Business Growth
  10. Major Roadblocks for the Market Growth
  11. Regulatory & Standard Landscape
  12. Value Chain Analysis
  13. Potential ATMP Treatment Analysis
  14. Pricing Analysis of Global Advanced Therapy Medicinal Products Market
  15. Use Case Analysis
  16. Pipeline Analysis
  17. Analysis on the Manufacturing Process
  18. Analysis of COVID-19 Impact on the Global Advanced Therapy Medicinal Products Market
  19. Analysis of End-User Market Share of Global Advanced Therapy Medicinal Products
  20. Competitive Positioning
  21. Competitive Landscape
  22. Market Share Analysis of Major Players (%), 2021
  23. Competitive Benchmarking
  24. Novartis AG.
  25. Takeda Pharmaceutical Company Limited
  26. Gilead Sciences, Inc.
  27. Bluebird Bio, Inc
  28. BioMarin Pharmaceutical Inc
  29. Vericel Corporation
  30. Mallinckrodt Pharmaceuticals
  31. UniQure N.V.
  32. JCR Pharmaceuticals Co., Ltd.
  33. Spark Therapeutics, Inc. (Parent Company: Roche)
  34. Kolon TissueGene, Inc.
  35. Global Advanced Therapy Medicinal Products Market Outlook
  36. By Value (USD million)
  37. By Product
  38. CAR-T Therapy, 2021-2031F (USD million)
  39. Gene Therapy, 2021-2031F (USD million)
  40. Cell Therapy, 2021-2031F (USD million)
  41. Tissue Engineered Product, 2021-2031F (USD million)
  42. By Disease
  43. Oncology, 2021-2031F (USD million)
  44. Genetic Disorders, 2021-2031F (USD million)
  45. CNS, 2021-2031F (USD million)
  46. Dermatology, 2021-2031F (USD million)
  47. Others, 2021-2031F (USD million)
  48. By End-User
  49. Hospitals & Clinics, 2021-2031F (USD million)
  50. Research & Academic Institutes, 2021-2031F (USD million)
  51. Global Advanced Therapy Medicinal Products Market by Region
  52. North America, 2021-2031F (USD million)
  53. Europe, 2021-2031F (USD million)
  54. Asia-Pacific, 2021-2031F (USD million)
  55. Latin America, 2021-2031F (USD million)
  56. Middle East & Africa, 2021-2031F (USD million)
  57. North America Advanced Therapy Medicinal Products Market Outlook
  58. By Value (USD million)
  59. By Product
  60. CAR-T Therapy, 2021-2031F (USD million
  61. Gene Therapy, 2021-2031F (USD million)
  62. Cell Therapy, 2021-2031F (USD million)
  63. Tissue Engineered Product, 2021-2031F (USD million)
  64. By Disease
  65. Oncology, 2021-2031F (USD million)
  66. Genetic Disorders, 2021-2031F (USD million)
  67. CNS, 2021-2031F (USD million)
  68. Dermatology, 2021-2031F (USD million)
  69. Others, 2021-2031F (USD million)
  70. By End-User
  71. Hospitals & Clinics, 2021-2031F (USD million)
  72. Research & Academic Institutes, 2021-2031F (USD million)
  73. By Country
  74. US, 2021-2031F (USD million)
  75. Canada, 2021-2031F (USD million)
  76. Europe Advanced Therapy Medicinal Products Market Outlook
  77. By Product
  78. By Disease
  79. By End User
  80. By Country
  81. UK, 2021-2031F (USD Million)
  82. Germany, 2021-2031F (USD Million)
  83. France, 2021-2031F (USD Million)
  84. Italy, 2021-2031F (USD Million)
  85. Spain, 2021-2031F (USD Million)
  86. Russia, 2021-2031F (USD Million)
  87. Netherlands, 2021-2031F (USD Million)
  88. Rest of Europe, 2021-2031F (USD Million)
  89. Asia Pacific Advanced Therapy Medicinal Products Market Outlook
  90. By Product
  91. By Disease
  92. By End User
  93. By Country
  94. China, 2021-2031F (USD Million)
  95. India, 2021-2031F (USD Million)
  96. Japan, 2021-2031F (USD Million)
  97. South Korea, 2021-2031F (USD Million)
  98. Singapore, 2021-2031F (USD Million)
  99. Australia, 2021-2031F (USD Million)
  100. Rest of Asia-Pacific, 2021-2031F (USD Million)
  101. Latin America Advanced Therapy Medicinal Products Market Outlook
  102. By Product
  103. By Disease
  104. By End User
  105. By Country
  106. Brazil, 2021-2031F (USD Million)
  107. Argentina, 2021-2031F (USD Million)
  108. Mexico, 2021-2031F (USD Million)
  109. Rest of Latin America, 2021-2031F (USD Million)
  110. Middle East & Africa Advanced Therapy Medicinal Products Market Outlook
  111. By Product
  112. By Disease
  113. By End User
  114. By Country
  115. GCC, 2021-2031F (USD Million)
  116. Israel, 2021-2031F (USD Million)
  117. South Africa, 2021-2031F (USD Million)
  118. Rest of Middle East & Africa, 2021-2031F (USD Million)

Preview Analysis

Request Insights
Inflation and Looming Recession to Haunt Businesses:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.


In The News

  • July 12, 2021: Quidel Corporation announced that it has received the CE Mark for two of its products, namely, Savanna multiplex molecular analyzer and Savanna RVP4 Assay (Respiratory Viral Panel-4). The Savanna system, which is an automated in-vitro diagnostic platform, can now be sold in the markets of Europe and other countries where the CE Mark is accepted.


Global In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market Highlights Over 2019 - 2028

The global in-vitro inflammatory bowel disease (IBD) market is estimated to garner a revenue of USD 2391.64 Million by the end of 2028, up from USD 1640 Million in 2019, by growing at a CAGR of 5.4% over the forecast period, i.e., 2021 – 2028. The growth of the market can be primarily attributed to the growing prevalence of inflammatory bowel disease worldwide, and therefore the need amongst individuals to diagnose the disease. According to the statistical report titled “The Global, Regional and National Burden of Inflammatory Bowel Disease in 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017”, the prevalence of IBD globally in the year 2017 recorded to 6.8 Million. Further, the statistics also stated that the age-standardized prevalence rate of the disease touched 84.3 per 100000 population in the year 2017, as compared to 79.5 per 100000 population in the year 1990. Moreover, the market is also anticipated to grow on account of the growing healthcare expenditure and the rising research activities in the field of gastro sciences.

In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market Graph

Get more information on this reportDownload Sample PDF

The global in-vitro inflammatory bowel disease (IBD) market is also expected to grow on account of the growing concern for the increasing incidences of digestive diseases worldwide and the increasing awareness amongst individuals to treat such diseases. According to the statistics by the Institute for Health Metrics and Evaluation (IHME), deaths caused due to digestive diseases around the globe increased from 726331.36 deaths in the year 2000 to 939281 deaths in the year 2019. 

Deaths due to Digestive Diseases Graph


Global In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market Regional Synopsis

Regionally, the global in-vitro inflammatory bowel disease (IBD) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is anticipated to hold the highest market share throughout the forecast period, backed by the increasing prevalence of IBD amongst the individuals in the region, followed by the presence of a strong healthcare network in countries such as the United States, as well as for the rising healthcare expenditure in the countries in the region. The market in the region garnered a revenue of USD 723.24 Million in the year 2019, and it is further expected to reach USD 1067.01 Million by the end of 2028. The market in the region is also anticipated to grow with the highest CAGR of 5.7% during the forecast period. 

On the other hand, the market in Europe is expected to hold the second-leading market share and attain a revenue of USD 915.66 Million by the end of 2028. Amongst the countries in the region, the market in Germany is anticipated to garner the second-largest revenue of USD 165.08 Million by the end of 2028, up from a revenue of USD 110.09 Million in 2019.

The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).


Growth Drivers and Challenges Impacting the Growth of the Global In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market

Growth Drivers

  • Increasing Prevalence of IBD
  • Rapid Research and Development in Gastro Sciences

Challenges

  • Stringent Product Approval Process


In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market Graph
Get more information on this report: Request Sample PDF

Global In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market Segmentation Synopsis

The global in-vitro inflammatory bowel disease (IBD) diagnostic market is segmented by product into assays/biomarkers and analyzers. Out of these, the assays/biomarkers segment is anticipated to hold the highest market share throughout the forecast period. The segment is also anticipated to grow with the highest CAGR of 5.6% during the forecast period. Further, on the basis of disease type, the market is segmented into ulcerative colitis and Crohn’s disease, out of which, the ulcerative colitis segment is anticipated to hold the highest market share and also grow with the highest CAGR of 5.7% during the forecast period. Based on disease stage, the market is segmented into mild, moderate, and severe, out of which, the severe segment is anticipated to hold the largest market revenue of USD 1225.89 Million by the end of 2028, up from a revenue of USD 823.27 Million in 2019. Further, on the basis of test type, the market is segmented into blood tests, stool tests, antibody tests, and biopsy. Out of these segments, the blood tests segment is anticipated to hold the highest market share and also attain a market revenue of USD 931.51 Million by the end of 2028. On the basis of patient demography, the market is segmented into pediatric, adults, and geriatric, out of which, the adults segment is anticipated to hold the largest revenue of USD 1592.15 Million by the end of 2028. The market is also segmented on the basis of end-user into hospitals, clinics, diagnostic laboratories, and others. Out of these segments, the hospitals segment is projected to hold the highest market share and also attain a revenue of USD 1297.52 Million by the end of 2028. Moreover, on the basis of test method, the market is segmented into PETIA, ELISA, rapid, and others, out of which, the ELISA segment is expected to garner the highest market revenue of USD 663.62 Million by the end of 2028, up from a revenue of USD 428.08 Million in 2019.


Key Companies Dominating the Market

Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global in-vitro inflammatory bowel disease (IBD) market that are included in our report are DiaSorin S.p.A., American Laboratory Products Company, Ltd. (d/b/a ALPCO Diagnostics), Quidel Corporation, CerTest Biotec, S.L., BUHLMANN Laboratories AG, BioSystems S.A., Inova Diagnostics, Inc. (Werfen), and others.


Deaths due to Digestive Diseases Graph

Key Questions Answered in the Report

1) What are the major factors driving the growth of the in-vitro inflammatory bowel disease (IBD) diagnostic market?

Ans: The growing prevalence of IBD is one of the major factors anticipated to drive the market growth.

2) What would be the CAGR of in-vitro inflammatory bowel disease (IBD) diagnostic market over the forecast period?

Ans: The market is anticipated to attain a CAGR of 5.4% over the forecast period, i.e., 2021-2028.

3) What are the challenges affecting the in-vitro inflammatory bowel disease (IBD) diagnostic market growth?

Ans: The stringent norms for product approval is one of the major factors estimated to hamper the market growth.

4) Which region will provide more business opportunities for growth of in-vitro inflammatory bowel disease (IBD) diagnostic market in future?

Ans: The market in Europe is projected to display significant growth opportunities during the forecast period.

5) Who are the major players dominating the in-vitro inflammatory bowel disease (IBD) diagnostic market?

Ans: The major players in the market are are DiaSorin S.p.A., American Laboratory Products Company, Ltd. (d/b/a ALPCO Diagnostics), Quidel Corporation, CerTest Biotec, S.L., BUHLMANN Laboratories AG, and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the in-vitro inflammatory bowel disease (IBD) market?

Ans: The market is segmented by product, disease type, disease stage, test type, patient demography, end user, test method, and by region.

8) Which segment captures the largest market size in test method segment in the in-vitro inflammatory bowel disease (IBD) market?

Ans: The ELISA segment is anticipated to hold largest market size of USD 663.62 Million by the end of 2028 and display significant growth opportunities in the years to come.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Submit RFP    Buy Now Download Research Report Sample